Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy | Primary Membranous Nephropathy | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-14 | NCT07765537 | |
| A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-14 | NCT07765524 | |
| A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma. | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Early phase 1 | 2026-06-05 | NCT07606937 |